Delos Capital
Overview
Delos Capital is a lower-middle market private equity investment firm based in New York City.\\The Fund was formed in 2013 to invest in complex processes through Control Buyouts, Strategic Partnerships and Distressed Buyouts in companies with EBITDA of $10 – $30 million.
Investment Focus
- Strong scientific foundation
- Experienced management team
- Clear clinical need
- Potential for significant impact on patient care
- Experienced management teams
- Established market presence
- Scalable business models
- Strong growth potential
- Competitive market positioning
- Proven financial performance
- Clear exit strategies
- Alignment with Delos Capital's values and investment philosophy
Portfolio Companies
Reach Delos Capital directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about Delos Capital
What sectors does Delos Capital invest in?
Delos Capital invests in Financial Services, Technology, Healthcare, Energy, Real Estate and Telecommunications, and is based in New York, New York, United States. Delos Capital is listed as a private investment firm in the ConnectSafely investor database.
What stage does Delos Capital invest at?
Delos Capital backs companies at Seed, Early Stage, Growth, Late Stage, Pre-IPO and Buyout, writing cheques of 10M - 50M.
Which regions does Delos Capital invest in?
Delos Capital invests across United States, Hong Kong and China.
What companies has Delos Capital invested in?
Delos Capital's portfolio includes Zenas BioPharma, TRexBio, Averna Therapeutics, Eccogene, Alpha-9 Oncology, Instylla, ALX Health and Atlas Keystone.
How do I contact Delos Capital?
Delos Capital's contact details — including phone and LinkedIn — are listed in the ConnectSafely investor database, along with its website and the LinkedIn profiles of the team.
Last updated · Source: ConnectSafely investor database
